Linked Life Data

12508842

Source:http://linkedlifedata.com/resource/pubmed/id/12508842

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2003-1-1
pubmed:abstractText
In April 2000, a 54-year-old woman underwent surgery for ovarian serous cell carcinoma (stage IIb). After initial treatment, the patient underwent a physical examination, ultrasound examination and measurement of serum CA-125 levels every month. Although neither diagnostic imaging (ultrasound and computed tomography) nor physical examination showed any evidence of recurrence, the CA-125 level rose slowly and continuously within the normal range. In March 2001, an increased accumulation of 18F-fluorodeoxyglucose (FDG) in the pelvic cavity was seen on a positron emission tomography (PET) scan obtained 2 weeks before a relapse of a malignant lesion was diagnosed by gadolinium-enhanced MRI (Gd-MRI). It is reasonable to suppose that FDG-PET is clinically useful for detecting an early, small region of relapsed ovarian cancer. Moreover, FDG-PET may be helpful for determining whether a patient who has a continuous rising CA-125 level within the normal range should be treated in the absence of relapse regions detected by conventional methods.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0914-7187
pubmed:author
pubmed:issnType
Print
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
491-3
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range.
pubmed:affiliation
Department of Obstetrics and Gynecology, Fukui Medical University, Yoshida, Japan.
pubmed:publicationType
Journal Article, Case Reports